A5012612478- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Retinoids in leukemia and cellular processes
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Advances in Oncology and Radiotherapy
- Global Cancer Incidence and Screening
- Advanced Breast Cancer Therapies
- Antioxidant Activity and Oxidative Stress
- Breast Lesions and Carcinomas
- Cancer Risks and Factors
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Economic and Financial Impacts of Cancer
- Innovations in Medical Education
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
- Inflammatory mediators and NSAID effects
- Cancer survivorship and care
- Software-Defined Networks and 5G
- Head and Neck Cancer Studies
- Male Breast Health Studies
Telefonica Research and Development
2023
Tumori Foundation
2023
European School of Oncology
2012-2020
European School of Oncology
2007-2020
MultiMedica
1994-2016
Istituti di Ricovero e Cura a Carattere Scientifico
1993-2016
Fondazione Salvatore Maugeri
2002-2013
Institut Jules Bordet
2010
Dana-Farber Brigham Cancer Center
2010
Brigham and Women's Hospital
2010
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
ContextRaloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic effects on breast and endometrial tissue estrogenic bone, lipid metabolism, blood clotting.ObjectiveTo determine whether women taking raloxifene have lower risk of invasive cancer.Design SettingThe Multiple Outcomes Raloxifene Evaluation (MORE), multicenter, randomized, double-blind trial, in which or placebo were followed up for median 40 months (SD, 3 years), from 1994 through 1998, at 180...
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years 5-year only ∼25% [2.Cardoso Spence D. Mertz S. et al.Global analysis...
Advanced breast cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the human epidermal growth factor receptor 2 (HER-2)-positive luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6].
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the HER-2-positive Luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6]. Implementation current knowledge highly variable among...
The 1st international Consensus Conference for Advanced Breast Cancer (ABC 1) took place on November 2011, in Lisbon.Consensus guidelines the management of this disease were developed.This manuscript summarizes these consensus guidelines.
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, it is remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5,6].
PURPOSE Monitoring of fenretinide (4HPR) levels, kinetics, and effects on retinal was performed in patients who participated a phase I trial continued to be treated for 5 years as III patients. Accumulation 4HPR the breast also assessed. PATIENTS AND METHODS Plasma concentrations 4HPR, its main metabolite N-(4-methoxyphenyl)retinamide (4MPR), retinol were assayed by high-performance liquid chromatography (HPLC) cancer orally with 200 mg/d 3-day drug interruption at end each month. RESULTS...
The possible association between the risk of breast cancer, blood level, and dietary intake preformed Vitamin A (retinol) beta-carotene was investigated in a case-control study carried out from May 1982 to June 1985. patients studied were 214 previously untreated individuals with T1-2, N0-1, M0 cancer admitted National Cancer Institute Milan 215 controls for conditions other than neoplastic or metabolic disorders. Both cases selected an age group ranging 30 65 years old. Plasma levels...
PURPOSE An increase in the incidence of endometrial cancer and a potential related mortality has been associated with administration 20 mg tamoxifen, dose adopted breast chemoprevention trials, thus urging studies on intermediate markers risk. PATIENTS AND METHODS Thirty-three women who received tamoxifen as adjuvant treatment underwent biopsy. Samples were divided for histologic examination, including quantitative analysis stromal:epithelial ratio, an assessment DNA ploidy proliferation by...
Journal Article N -(4-hydroxyphenyl)retinamide: a Potent Inducer of Apoptosis in Human Neuroblastoma Cells Get access Agnese Mariotti, Mariotti *Affiliations authors: Dipartimento di Genetica e Microbiologia, A. Buzzati Traverse, Universitàdi PaviaPavia, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Edoardo Marcora, Marcora Giuseppe Bunone, Bunone Alberto Costa, Costa European Institute OncologyMilano, Umberto Veronesi, Veronesi Istituto Nazionale...
Journal Article Effect of the Synthetic Retinoid Fenretinide on Dark Adaptation and Ocular Surface Get access Andrea Decensi, Decensi Department Medical Oncology II, National Institute for Cancer ResearchGenoa, Italy Correspondence to : M.D., Servizio di Oncologia Medica Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10 – 16132 Genoa, Italy. Search other works by this author on: Oxford Academic PubMed Google Scholar Rosalba Torrisi, Torrisi Anna Polizzi, Polizzi University...